Expressions and clinical significance of HtrA2 gene in acute myeloid leukemia patients
10.3969/j.issn.1006-5725.2017.03.036
- VernacularTitle:促凋亡基因HtrA2在急性髓系白血病中的表达及临床意义
- Author:
Nan WANG
;
Lianjun XIONG
;
Xiaolu MA
- Keywords:
Acute myeloid leukemia;
Gene HtrA2;
Quantitative real-time PCR
- From:
The Journal of Practical Medicine
2017;33(3):466-470
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the expression and clinical significance of proapoptotic genes HtraA2 in acute myeloid leukemia.Methods 78 cases of AML patients were divided into newly diagnosed AML group,complete remission group and hard flag group,and another 25 cases treated at the same period were set as the control group.The boue marrow and peripheral blood samples were collected from all the groups for total RNA extraction and detection of expressed HtrA2.The HtrA2 expressions were compared among thc groups.Finally 17 patients were followed up for 1～56 months.Results The HtrA2 expression levels of 3 groups were significantly different (x2 =35.13,P ＜ 0.05),with the ratio of maximum to minimum values up to 68.76.There were no statistically significant differences in the relative expression of gcnes HtrA2 among the FAB type (F =0.004,P ＞ 0.05).HtrA2 gene expression after treatment was significantly higher than before treatment in the patients followed up (P ＞ 0.05).HtrA2 gene might affect the survival time of patients (Wald =4.979,P ＜ 0.05),but age and gender had no influence on survival states (Wald =2.426 and 0.833,P ＞ 0.05).Survival curve analysis showed that the median smvival time was 34.50 months in the patients followed up.Conclusion The expression level of HtrA2 can be beneficial for the diagnosis,treatment and prognostic evaluation of AML.
